Evidence map›Paper›PMID 40261715›Full record

ArticleKidney3602025

Real-World Tolvaptan Use in Autosomal Dominant Polycystic Kidney Disease: Insights from Two US Medical Centers.

Vinamratha Rao, Shahed Ammar, Abrar Alshorman, Michelle Fravel, Kerri A McGreal, Franz T Winklhofer, Lama Noureddine, Diana I Jalal, Alan S L Yu, Reem A Mustafa

Abstract read
In one paragraph

Article in Kidney360, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Vinamratha RaoDepartment of Medicine, University of Kansas Medical Center, Kansas City, Kansas.ORCID 0000-0002-6934-6021
Shahed AmmarDepartment of Pharmacy Practice and Science, University of Iowa College of Pharmacy, Iowa City, Iowa.ORCID 0009-0001-3154-4612
Abrar AlshormanDepartment of Medicine, University of Kansas Medical Center, Kansas City, Kansas.ORCID 0000-0002-5284-0023
Michelle FravelDepartment of Pharmacy Practice and Science, University of Iowa College of Pharmacy, Iowa City, Iowa.ORCID 0000-0002-0697-2957
Kerri A McGrealDepartment of Medicine, University of Kansas Medical Center, Kansas City, Kansas.ORCID 0000-0001-8097-6537
Franz T WinklhoferDepartment of Medicine, University of Kansas Medical Center, Kansas City, Kansas.ORCID 0009-0005-8094-8524
Lama NoureddineDepartment of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa.ORCID 0000-0003-0706-0383
Diana I JalalDepartment of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa.ORCID 0000-0002-1975-8650
Alan S L YuDepartment of Medicine, University of Kansas Medical Center, Kansas City, Kansas.ORCID 0000-0002-1776-2533
Reem A MustafaDepartment of Medicine, University of Kansas Medical Center, Kansas City, Kansas.ORCID 0000-0002-2091-0875

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ADPKDchronic kidney diseaseclinical nephrologycohort studiescystic kidneyepidemiology and outcomegenetic renal diseaseoutcomespolycystic kidney diseasevasopressin

Identifiers

PMID40261715
PMCPMC12483031

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.